Recombinant Proteins

Recombinant Proteins
Accession Number

Proteins prepared by recombinant DNA technology.

DrugDrug Description
Denileukin diftitoxA recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
RasburicaseA recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
AlbiglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
Elosulfase alfaA lysosomal glycosaminoglycan (GAG)-specific enzyme indicated as an enzyme replacement therapy for Mucopolysaccharidosis type IV A.
Corifollitropin alfaA FSH analogue indicated for Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.
Turoctocog alfaAn antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
DulanerminDulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
Moroctocog alfaA recombinant Factor VIII used to treat hemophilia A to control bleeding.
Antihemophilic factor (recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...
ElapegademaseA recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency.
Turoctocog alfa pegolTuroctocog alfa pegol is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to...
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
EndostarEndostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms.
Albutrepenonacog alfaA recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
TagraxofuspA CD123-directed cytotoxin used to treat blastic plasmacytoid dendritic cell neoplasm.
PegilodecakinPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Rurioctocog alfa pegolA pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
Cintredekin besudotoxInvestigated for use/treatment in brain cancer.
Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
GI-5005Investigated for use/treatment in hepatitis (viral, C).
RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
AtaciceptInvestigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
BaminerceptInvestigated for use/treatment in rheumatoid arthritis.
AfliberceptA vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer
Asfotase alfaAn enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
TrebananibTrebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon...
SotaterceptA recombinant activin receptor fusion protein used to treat pulmonary arterial hypertension.
Vanutide cridificarVanutide cridificar has been investigated for the treatment of Alzheimer Disease.
Abicipar PegolAbicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.
BlisibimodBlisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
ConberceptConbercept has been investigated for the basic science of Age-related Macular Degeneration.
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
AlbusomatropinAlbusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency.
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
TebentafuspA bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma.
DAS-181DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).
Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
ALT-801ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Onasemnogene abeparvovecA gene therapy used to treat neonatal and infant patients with spinal muscular atrophy caused by bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
BNT162b1 SARS-CoV-2 VaccineBNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding...
TozinameranAn mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus.
Bizalimogene ralaplasmidBizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade...
OtlertuzumabOtlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Efineptakin alfaEfineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more...
PidacmeranPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
BNT-162A1BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
EpiVacCoronaEpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently...
InbakiceptNot Available
Efanesoctocog alfaA recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A.
TengonerminTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
PegloticaseA recombinant uricase used for the treatment of chronic gout in adult patients refractory to conventional therapy.
Olipudase alfaA recombinant human acid sphingomyelinase used to treat Acid Sphingomyelinase Deficiency (ASMD) in children and adults.
Valoctocogene roxaparvovecAn adeno-associated virus serotype 5 (AAV5)-based gene therapy containing a coagulation factor VIII complementary DNA used to treat severe hemophilia A.
MP-0250Not Annotated
Nadofaragene firadenovecA non-replicating adenoviral vector-based gene therapy used to treat high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
GI-6207Not Annotated
INO-4800INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that...
CVnCoV VaccineThe CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate...
Rocakinogene sifuplasmidRocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma (GBM)).
Eflepedocokin alfaEflepedocokin alfa is a recombinant IL-22-Fc fusion protein manufactured in Chinese hamster ovary cells that is composed of 2 human interleukin 22 (IL-22) molecules linked to an immunoglobulin constant region...
FamtozinameranA component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineages BA.4 and BA.5.
Retlirafusp alfaNot Annotated
CDX-1135CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and...
Tralesinidase alfaTralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2. It is being investigated for the treatment of mucopolysaccharidosis type...
Apadamtase alfaA recombinant human ADAMTS13 for enzyme replacement therapy in patients with congenital thrombotic thrombocytopenic purpura.
Pegunigalsidase alfaA recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease.
EDI-200EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
TelitaciceptNot Annotated
AcazicolceptNot Annotated
Eftansomatropin alfaEftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment. It is under investigation for the treatment of growth hormone deficiency.
Drugs & Drug Targets
Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
Denileukin diftitoxCytokine receptor common subunit gammatarget
Denileukin diftitoxInterleukin-2 receptor subunit betatarget
RasburicaseUric acidtarget
OnerceptTumor necrosis factortarget
AlbiglutideGlucagon-like peptide 1 receptortarget
DulaglutideGlucagon-like peptide 1 receptortarget
Corifollitropin alfaFollicle-stimulating hormone receptortarget
Turoctocog alfaCoagulation factor IXtarget
Turoctocog alfaCoagulation factor Xtarget
Turoctocog alfaProthrombintarget
Moroctocog alfaCoagulation factor Xtarget
Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
Moroctocog alfaCoagulation factor IXtarget
Moroctocog alfaAsialoglycoprotein receptor 2target
Moroctocog alfa78 kDa glucose-regulated proteintarget
Moroctocog alfaCalreticulintarget
Moroctocog alfaCalnexintarget
Moroctocog alfaProtein ERGIC-53target
Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
Moroctocog alfaMultiple coagulation factor deficiency protein 2target
Moroctocog alfavon Willebrand factortarget
Moroctocog alfaProthrombinenzyme
Moroctocog alfaVitamin K-dependent protein Cenzyme
Antihemophilic factor (recombinant), PEGylatedvon Willebrand factortarget
Antihemophilic factor (recombinant), PEGylatedvon Willebrand factorcarrier
Turoctocog alfa pegolVitamin K-dependent protein Cenzyme
Turoctocog alfa pegolCoagulation factor Xenzyme
Turoctocog alfa pegolCoagulation factor IXtarget
Turoctocog alfa pegolCoagulation factor Xtarget
Turoctocog alfa pegolProthrombintarget
Turoctocog alfa pegolvon Willebrand factortarget
Albutrepenonacog alfaCoagulation factor Xtarget
Albutrepenonacog alfaCoagulation factor VIIIenzyme
TagraxofuspInterleukin-3 receptor subunit alphatarget
Rurioctocog alfa pegolvon Willebrand factortarget
Rurioctocog alfa pegolCoagulation factor VIIItarget
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Cintredekin besudotoxInterleukin-13target
Oportuzumab monatoxEpithelial cell adhesion moleculetarget
RomiplostimThrombopoietin receptortarget
PRO-542Free fatty acid receptor 4target
RilonaceptInterleukin-1 betatarget
RilonaceptInterleukin-1 alphatarget
RilonaceptInterleukin-1 receptor antagonist proteintarget
AfliberceptVascular endothelial growth factor Atarget
AfliberceptPlacenta growth factortarget
AfliberceptVascular endothelial growth factor Btarget
Asfotase alfaPyrophosphatetarget
SotaterceptActivin receptor type-2Atarget
SotaterceptActivin receptor type-1Btarget
SotaterceptGrowth/differentiation factor 8target
SotaterceptGrowth/differentiation factor 11target
TebentafuspMelanocyte protein PMELtarget
OtlertuzumabLeukocyte antigen CD37target
Efanesoctocog alfaLow-density lipoprotein receptor-related protein 2target
Efanesoctocog alfaBasement membrane-specific heparan sulfate proteoglycan core proteintarget
Efanesoctocog alfaCoagulation factor IXtarget
Efanesoctocog alfaCoagulation factor Xtarget
PegloticaseUric acidtarget
Valoctocogene roxaparvovecCoagulation factor VIII (F8)target
Apadamtase alfavon Willebrand factortarget
Pegunigalsidase alfaGlobotriaosylceramidetarget